Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hysingla ER in Children (12-17) With Moderate to Severe Pain
NCT02542098Phase 2Withdrawn
- Sponsor
- Purdue Pharma
- Start
- Jan 2017
- Primary completion
- Jul 2019
01
Overview
Phase 2, open-label, single-arm trial of oxycodone in pain, sponsored by Purdue Pharma. Primary endpoints: Number of participants with adverse events, Apparent volume of distribution of hydrocodone at 4 weeks and 1 more. Planned start Jan 2017; status: withdrawn.
02
Drugs
oxycodone
03
Conditions
pain
Beyond the preview
Go deeper on NCT02542098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02542098.